hotspot -WSS

hotspot

author：fashion 2025-10-01 17:05:47 - browse：8

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： What to know about the judge who will handle the Trump case

leisure time

WSS

Health AI: on the border between health care and tech

Bird flu researchers hone in on Finland’s mink farms

Illinois Supreme Court finds assault weapons ban constitutional

Opioid cravings were reduced by anti

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Medicare Advantage enrollment hits roughly 33.4 million

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Obamacare plans could cover weight loss drugs

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Novo Nordisk touts Wegovy study, but still struggling with supply

Medical leaders decry Supreme Court decision on affirmative action

Montana youths win climate lawsuit against state for promoting fossil fuels

Supreme Court strikes down use of affirmative action

Opioid cravings were reduced by anti

Medicare details structure of new drug price negotiation program

Schizophrenia gene found to be linked to cells' energy dysfunction

hotspot

Secretariat’s lessons for human medicine

What to know about the judge who will handle the Trump case

Congress may force more Covid

Schizophrenia gene found to be linked to cells' energy dysfunction

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

entertainment

leisure time

leisure time

knowledge